Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have earned a consensus rating of “Moderate Buy” from the nine brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $48.71.

COLL has been the topic of a number of research reports. Barclays cut their target price on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 19th. Truist Financial initiated coverage on shares of Collegium Pharmaceutical in a research report on Wednesday, September 9th. They set a “buy” rating and a $49.00 price target for the company. Wall Street Zen downgraded shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings lowered shares of Collegium Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, September 4th. Finally, Zacks Research lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new position in Collegium Pharmaceutical in the second quarter valued at about $196,972,000. Jupiter Topco LLC acquired a new position in shares of Collegium Pharmaceutical during the 2nd quarter worth about $77,743,000. Janus Henderson Group PLC increased its stake in shares of Collegium Pharmaceutical by 26.0% in the 1st quarter. Janus Henderson Group PLC now owns 1,825,651 shares of the specialty pharmaceutical company’s stock valued at $60,358,000 after acquiring an additional 377,073 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Collegium Pharmaceutical by 0.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 833,192 shares of the specialty pharmaceutical company’s stock valued at $27,551,000 after acquiring an additional 2,712 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its position in shares of Collegium Pharmaceutical by 29.4% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 703,528 shares of the specialty pharmaceutical company’s stock valued at $23,266,000 after acquiring an additional 159,755 shares during the period.

Collegium Pharmaceutical Trading Up 0.8%

COLL stock opened at $22.64 on Friday. The company has a market cap of $737.16 million, a P/E ratio of 18.26 and a beta of 0.72. Collegium Pharmaceutical has a twelve month low of $21.65 and a twelve month high of $50.79. The company has a quick ratio of 0.84, a current ratio of 1.03 and a debt-to-equity ratio of 3.32. The business has a fifty day moving average of $28.12 and a 200-day moving average of $32.24.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.20. The business had revenue of $199.88 million for the quarter, compared to analysts’ expectations of $199.62 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The firm’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter last year, the business earned $1.68 earnings per share. As a group, equities research analysts expect that Collegium Pharmaceutical will post 6.19 EPS for the current year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for patients with central nervous system disorders. The company’s portfolio includes treatments for pain and attention deficit hyperactivity disorder (ADHD), with an emphasis on products that address unmet patient and healthcare-provider needs.

Collegium’s pain portfolio includes Xtampza ER, an extended-release oxycodone product designed with abuse-deterrent properties; Nucynta and Nucynta ER, which contain tapentadol and are used to treat certain types of acute and chronic pain; and Belbuca, a buprenorphine buccal film for the management of chronic pain.